6533b829fe1ef96bd128ad17
RESEARCH PRODUCT
Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases
Harry J. De KoningIvica GrgurevićPatrick S. KamathLaurent CasteraLaurent CasteraEmmanuel TsochatzisFrank LammertFrank LammertIsabel GrauperaAnn T. MaNúria FabrellasDominique RoulotPere GinèsMª Alba DiazSalvador AugustinAndrea MartiniVincent Wai-sun WongJudit PichRosa Maria MorillasPhilip N. NewsomeMiquel Serra-burrielMaja ThieleAleksander KragPhillipp HartmannRobert J. De KnegtMichael P MannsMontserrat García-retortilloJörn M. SchattenbergIndra Neil GuhaAlina M. AllenLlorenç Caballeríasubject
Liver Cirrhosismedicine.medical_specialtyCirrosi hepàtica - DiagnòsticCirrhosisFibrosiBiopsy:enfermedades del sistema digestivo::enfermedades hepáticas::cirrosis hepática [ENFERMEDADES]Population:Digestive System Diseases::Liver Diseases::Liver Cirrhosis [DISEASES]:Otros calificadores::/diagnóstico [Otros calificadores]DiseaseFetge -- Malalties:Diagnosis::Diagnostic Techniques and Procedures::Mass Screening [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]AsymptomaticGastroenterologyGlobal Burden of DiseaseLiver diseaseHepatitis B ChronicSDG 3 - Good Health and Well-beingLiver Function TestsNon-alcoholic Fatty Liver DiseaseRisk FactorsFibrosisInternal medicinePrevalenceCribatge (Medicina):Other subheadings::/diagnosis [Other subheadings]:diagnóstico::técnicas y procedimientos diagnósticos::cribado sistemático [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]HumansMass ScreeningMedicineeducationliver fibrosiseducation.field_of_studyHepatologybusiness.industryFatty liverCirrosiHepatitis C Chronicmedicine.diseaseEarly DiagnosisLiverDisease ProgressionElasticity Imaging Techniquesmedicine.symptomTransient elastographybusinessdescription
Population screening; Liver fibrosis; Early diagnosis Cribratge de població; Fibrosi hepàtica; Diagnòstic precoç Cribado de población; Fibrosis hepática; Diagnóstico precoz Cirrhosis, highly prevalent worldwide, develops after years of hepatic inflammation triggering progressive fibrosis. Currently, the main etiologies of cirrhosis are non-alcoholic fatty liver disease and alcohol-related liver disease, although chronic hepatitis B and C infections are still major etiological factors in some areas of the world. Recent studies have shown that liver fibrosis can be assessed with relatively high accuracy noninvasively by serological tests, transient elastography, and radiological methods. These modalities may be utilized for screening for liver fibrosis in at-risk populations. Thus far, a limited number of population-based studies using noninvasive tests in different areas of the world indicate that a significant percentage of subjects without known liver disease (around 5% in general populations and a higher rate −18% to 27%-in populations with risk factors for liver disease) have significant undetected liver fibrosis or established cirrhosis. Larger international studies are required to show the harms and benefits before concluding that screening for liver fibrosis should be applied to populations at risk for chronic liver diseases. Screening for liver fibrosis has the potential for changing the current approach from diagnosing chronic liver diseases late when patients have already developed complications of cirrhosis to diagnosing liver fibrosis in asymptomatic subjects providing the opportunity of preventing disease progression. LiverScreen Consortium and the European Commission under the H20/20 program (847989); AGAUR (2017SGR-01281); Centro de Investigacion Biomedica en Enfermedades Hepaticas y Digestivas; Fundación de Investigación Sanitaria, cofunded by Instituto Carlos III–Subdirección General de Evaluación and the European Regional Development Fund (PI18/01330, PI18/00662, and PI18/00862); and Gilead’s Investigator–sponsored research program (IN-ES-989-5309)
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2022-01-01 | Hepatology |